Procurement of reagents, materials and related products compatible with the Customer's Aviti24 equipment

This tender focuses on supplying specific reagents and materials compatible with Aviti24 equipment. Success hinges on demonstrating technical compliance, competitive pricing, and efficient delivery, leveraging the provided technical specification as a direct template. While social and green procurement are absent, a focus on reliability and product quality will be key differentiators.

Reliable Supply of Essential Aviti24 Compatible Reagents

Competitive and Transparent Pricing for Critical Lab Supplies

Seamless Integration and Technical Compliance

Meticulously map all products offered against the '2026/80 Tehniskā specifikācija'. Ensure product descriptions, manufacturers, and specifications precisely match or exceed requirements. Provide clear evidence of compatibility with Aviti24 equipment.

Conduct thorough cost analysis to offer the most competitive pricing possible. Consider volume discounts or early payment terms if applicable, though not explicitly requested. Ensure all costs are transparent and align with the template.

Adhere strictly to all submission deadlines and formatting requirements. Double-check all documents for completeness and accuracy, especially the exclusion and eligibility criteria. Utilize the provided templates precisely.

The '2026/80 Tehniskā specifikācija' is the core of the technical and financial offer. Ensure every field is completed accurately, product names, manufacturers, and prices are precise, and that all listed items are indeed compatible with Aviti24 equipment. Any deviation or omission here is a direct failure.

Given the lack of explicit evaluation criteria, it's highly probable that price will be a significant, if not the primary, deciding factor. Aim for highly competitive pricing while ensuring profitability and the ability to maintain supply.

While not explicitly requested, demonstrating a robust and reliable supply chain for these specific reagents can be a subtle differentiator. Mentioning lead times and stock availability can provide confidence to the buyer.

Thoroughly review and confirm compliance with all mandatory exclusion and eligibility grounds in 'Iepirkuma priekšmeta prasības, 1.versija'. Any misstep here will lead to immediate disqualification.

The specification emphasizes Element Biosciences. If your offering includes alternatives, ensure they are clearly identified and justified for compatibility. Prioritize Element Biosciences products where possible to align with the stated preference.

This tender presents a moderate quality assessment, demonstrating good procedural clarity and data consistency, but is significantly hampered by concerns regarding fairness due to potentially tailored technical requirements and restricted document access.

The tender defines an open procedure, has a reasonable submission deadline (31 days), and uses an appropriate CPV code. It is EU funded and subject to WTO/GPA, indicating adherence to broader regulations. However, the flagged 'Restricted document access' is a significant concern for legal compliance regarding transparency and equal access to procurement information.

The tender description, procedure type, and submission requirements are clearly stated. AI-extracted requirements are generally clear. However, the absence of explicitly extracted evaluation criteria, despite a document claiming to contain them, and the automated flag for 'Missing evaluation criteria' significantly reduce clarity for bidders. The specificity of 'primarily from Element Biosciences' could also be clearer regarding alternatives.

Basic information, financial details, timeline, and classification are comprehensively provided. All four tender documents are listed. However, the 'Restricted document access' means that not all necessary information may be fully available to all potential bidders. The absence of clearly defined and extracted evaluation criteria also represents a significant gap in completeness.

This category is significantly impacted. The requirement for products 'primarily from Element Biosciences' strongly suggests tailoring to a specific manufacturer, severely limiting competition and fairness. Furthermore, 'Restricted document access' creates an uneven playing field, and the lack of clear evaluation criteria undermines transparency and objectivity. While e-procurement is enabled and the value is disclosed, these critical issues lead to a low score.

Electronic submission is supported, and the contract duration is specified. However, the 'Restricted document access' implies potential difficulties in obtaining essential tender documents, which reduces practicality. The contract start date is not provided, only the duration.

Most key fields are populated, and dates are logical and consistent. There are no reported disputes or suspensions. A minor inconsistency exists between the 'E-Procurement' characteristic and an automated check flagging 'No e-submission', which is assumed to be an error in the automated check given other information. The contradiction regarding evaluation criteria (document claims to have them, but they are flagged as missing/not extracted) is also a consistency issue within the provided data.

The tender is EU funded, which often implies higher standards. However, there is no explicit mention or integration of green procurement, social aspects, or innovation focus within the tender requirements or description. Automated checks confirm the absence of these criteria.